CO5580741A2 - Composicion farmaceutica que comprende un agonista de receptor de 5ht1 - Google Patents
Composicion farmaceutica que comprende un agonista de receptor de 5ht1Info
- Publication number
- CO5580741A2 CO5580741A2 CO04052110A CO04052110A CO5580741A2 CO 5580741 A2 CO5580741 A2 CO 5580741A2 CO 04052110 A CO04052110 A CO 04052110A CO 04052110 A CO04052110 A CO 04052110A CO 5580741 A2 CO5580741 A2 CO 5580741A2
- Authority
- CO
- Colombia
- Prior art keywords
- active ingredient
- sumatriptan
- dose
- pharmaceutical composition
- minutes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
1.- Una composición farmacéutica en forma de dosis sólida para administración oral que comprende sumatriptán o un derivado farmacéuticamente aceptable del mismo como ingrediente activo, en donde más que aproximadamente 70%, preferiblemente más que aproximadamente 80%, muy preferiblemente más que aproximadamente 90%, del ingrediente activo se disuelve en el fluido gástrico simulado (SGF) dentro de cinco minutos en un aparato de USPII a la velocidad de paletas discriminatoria de aproximadamente 10 rpm.2.- Una composición farmacéutica en forma de dosis sólida para administración oral que comprende sumatriptán o un derivado farmacéuticamente aceptable del mismo como ingrediente activo, en donde más que aproximadamente 90%, preferiblemente más que aproximadamente 95%, del ingrediente activo se disuelve en el fluido gástrico simulado (SGF) dentro de cinco minutos en un aparato de USPII a la velocidad de paletas discriminatoria de aproximadamente 30 rpm.3.- Una composición farmacéutica en forma de dosis sólida para administración oral que comprende sumatriptán o un derivado farmacéuticamente aceptable del mismo como ingrediente activo,en donde la administración de una sola dosis en pacientes humanos provee un incremento de más que o igual a aproximadamente 20%, preferiblemente más que o igual a aproximadamente 25%, en la media de la concentración en el plasma de sumatriptán in vivo a aproximadamente 15 minutos después de la dosis en relación con una formulación en forma de dosis sólida estándar de dicho ingrediente activo.4.- Una composición farmacéutica en forma de dosis sólida para administración oral que comprende sumatriptán o un derivado farmacéuticamente aceptable del mismo como ingrediente activo, en donde la administración de una sola dosis en pacientes humanos provee un incremento de más que o igual a aproximadamente 20%, preferiblemente más que o igual a aproximadamente 25%, en la media de la concentración en el plasma de sumatriptán in vivo a aproximadamente 20 minutos después de la dosis en relación con una formulación en forma de dosis sólida estándar de dicho ingrediente activo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129117.8A GB0129117D0 (en) | 2001-12-05 | 2001-12-05 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580741A2 true CO5580741A2 (es) | 2005-11-30 |
Family
ID=9927051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04052110A CO5580741A2 (es) | 2001-12-05 | 2004-06-03 | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20050032867A1 (es) |
| EP (2) | EP1527773A1 (es) |
| JP (1) | JP3699969B2 (es) |
| KR (1) | KR100591237B1 (es) |
| CN (1) | CN1289069C (es) |
| AR (1) | AR037627A1 (es) |
| AT (1) | ATE291900T1 (es) |
| AU (1) | AU2002358602B2 (es) |
| BR (1) | BR0214497A (es) |
| CA (1) | CA2469019C (es) |
| CO (1) | CO5580741A2 (es) |
| DE (1) | DE60203537T2 (es) |
| ES (1) | ES2236608T3 (es) |
| FI (1) | FI20022128A (es) |
| GB (1) | GB0129117D0 (es) |
| HK (1) | HK1069111A1 (es) |
| HU (1) | HU229313B1 (es) |
| IL (1) | IL161997A (es) |
| IS (1) | IS2481B (es) |
| MX (1) | MXPA04005420A (es) |
| MY (1) | MY129314A (es) |
| NO (1) | NO329896B1 (es) |
| NZ (1) | NZ532829A (es) |
| PL (1) | PL194702B1 (es) |
| PT (1) | PT1450770E (es) |
| RU (1) | RU2285526C2 (es) |
| TW (1) | TWI240638B (es) |
| WO (1) | WO2003047552A2 (es) |
| ZA (1) | ZA200403849B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| BRPI0409127A (pt) * | 2003-04-11 | 2006-03-28 | Pfizer | combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio |
| CA2527368A1 (en) * | 2003-06-06 | 2004-12-23 | Glaxo Group Limited | Pharmaceutical composition |
| EP1750677B1 (en) * | 2004-05-28 | 2017-02-01 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| NZ589750A (en) | 2004-10-21 | 2012-07-27 | Aptalis Pharmatech Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| EP1954298A4 (en) * | 2005-11-28 | 2012-10-31 | Imaginot Pty Ltd | DISPENSING SYSTEM FOR ORAL THERAPEUTIC CONNECTION |
| CN101431895A (zh) * | 2006-05-01 | 2009-05-13 | 卡普里康制药公司 | 新颖的曲坦制剂和制备它们的方法 |
| WO2008039358A2 (en) * | 2006-09-30 | 2008-04-03 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
| JP5309262B2 (ja) | 2009-12-02 | 2013-10-09 | アプタリス ファーマ リミテッド | フェキソフェナジン・マイクロカプセル及びそれを含む組成物 |
| US11364225B2 (en) | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468504A (en) * | 1990-12-21 | 1995-11-21 | Laboratoires Glaxo S.A. | Effervescent pharmaceutical compositions |
| GB9027827D0 (en) * | 1990-12-21 | 1991-02-13 | Glaxo Laboratoires | Pharmaceutical compositions |
| GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
| US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
| US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| GB9704524D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Composition |
| GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| WO1999043306A1 (en) * | 1998-02-26 | 1999-09-02 | Banyu Pharmaceutical Co., Ltd. | An orally disintegrating composition and its manufacturing method |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| EP1246668B1 (en) * | 1999-12-01 | 2005-11-30 | Natco Pharma Limited | An rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| US20020001617A1 (en) * | 2000-05-26 | 2002-01-03 | Chang-Hyun Lee | Rapidly disintegrating tablet and process for the manufacture thereof |
| US20030008005A1 (en) * | 2001-07-05 | 2003-01-09 | R.T. Alamo Ventures, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
-
2001
- 2001-12-05 GB GBGB0129117.8A patent/GB0129117D0/en not_active Ceased
-
2002
- 2002-12-03 TW TW091134979A patent/TWI240638B/zh not_active IP Right Cessation
- 2002-12-03 FI FI20022128A patent/FI20022128A/fi not_active Application Discontinuation
- 2002-12-03 MY MYPI20024534A patent/MY129314A/en unknown
- 2002-12-03 NO NO20025805A patent/NO329896B1/no not_active IP Right Cessation
- 2002-12-03 AR ARP020104674A patent/AR037627A1/es unknown
- 2002-12-04 BR BR0214497-2A patent/BR0214497A/pt not_active Application Discontinuation
- 2002-12-04 PL PL02370669A patent/PL194702B1/pl unknown
- 2002-12-04 KR KR1020047008687A patent/KR100591237B1/ko active IP Right Grant
- 2002-12-04 RU RU2004120292/15A patent/RU2285526C2/ru not_active IP Right Cessation
- 2002-12-04 HU HU0402178A patent/HU229313B1/hu unknown
- 2002-12-04 PT PT02792887T patent/PT1450770E/pt unknown
- 2002-12-04 US US10/497,749 patent/US20050032867A1/en not_active Abandoned
- 2002-12-04 EP EP05075288A patent/EP1527773A1/en not_active Withdrawn
- 2002-12-04 CA CA002469019A patent/CA2469019C/en not_active Expired - Lifetime
- 2002-12-04 CN CNB028244184A patent/CN1289069C/zh not_active Expired - Fee Related
- 2002-12-04 DE DE60203537T patent/DE60203537T2/de not_active Expired - Lifetime
- 2002-12-04 WO PCT/EP2002/013715 patent/WO2003047552A2/en active IP Right Grant
- 2002-12-04 MX MXPA04005420A patent/MXPA04005420A/es active IP Right Grant
- 2002-12-04 EP EP02792887A patent/EP1450770B1/en not_active Expired - Lifetime
- 2002-12-04 NZ NZ532829A patent/NZ532829A/en not_active IP Right Cessation
- 2002-12-04 ES ES02792887T patent/ES2236608T3/es not_active Expired - Lifetime
- 2002-12-04 IL IL16199702A patent/IL161997A/xx active IP Right Grant
- 2002-12-04 AT AT02792887T patent/ATE291900T1/de active
- 2002-12-04 AU AU2002358602A patent/AU2002358602B2/en not_active Expired
- 2002-12-04 JP JP2003548808A patent/JP3699969B2/ja not_active Expired - Lifetime
-
2004
- 2004-05-19 ZA ZA2004/03849A patent/ZA200403849B/en unknown
- 2004-06-03 IS IS7293A patent/IS2481B/is unknown
- 2004-06-03 CO CO04052110A patent/CO5580741A2/es active IP Right Grant
-
2005
- 2005-02-28 HK HK05101699A patent/HK1069111A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
| WO2018005695A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
| CR6458A (es) | Composiciones de valdecoxib | |
| NO20061859L (no) | OROS Push Stick for kontrollert tilforsel av aktive midler | |
| HK1073427A1 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes | |
| BRPI0708068A2 (pt) | pelìculas bucais passíveis de desintegração | |
| NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
| UY25544A1 (es) | Forma de dosificación de nefazodona | |
| MXPA05008838A (es) | Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht. | |
| LU91882I2 (fr) | Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| UA85359C2 (ru) | Таблетка, содержащая гранулированный материал с kmd-3213 | |
| RS50768B (sr) | Režim doziranja i farmaceutska formulacija za urgentnu zaštitu | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| CY1110184T1 (el) | Φαρμακευτικη συνθεση για μαλακες καψουλες για χορηγηση απο το στομα η οποια περιεχει βινορελβινη και μεθοδος θεραπειας | |
| BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
| JP2006522011A (ja) | 安定なカルプロフェン組成物 | |
| NO20052313L (no) | Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av | |
| AR043370A1 (es) | Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga | |
| JP4812394B2 (ja) | 鎮痛用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |